Stevenage Bioscience Catalyst Featured in BBC Coverage of Oxford Cambridge Growth Corridor
Stevenage Bioscience Catalyst has been featured on BBC News as part of coverage examining the Oxford Cambridge Growth Corridor and its potential economic impact.
The article reports that the corridor could contribute up to £78bn to the UK economy by 2035, driven by knowledge intensive industries including life sciences and advanced engineering.
Two companies based at Stevenage Bioscience Catalyst were featured in the piece: Complement Therapeutics and Autifony Therapeutics. Complement Therapeutics has grown from two employees to more than 20 over four years and recently received approval to begin clinical trials for its programme targeting age related macular degeneration. Autifony Therapeutics continues to progress its neuroscience pipeline from its base in Stevenage.
Further broadcast coverage is expected on BBC One East and BBC Three Counties Radio on 12 February 2026.
